Production (Stage)
Neumora Therapeutics, Inc.
NMRA
$1.02
$0.209925.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 67.01M | 62.54M | 56.76M | 56.01M | 50.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 274.33M | 263.46M | 250.64M | 230.86M | 209.10M |
| Operating Income | -274.33M | -263.46M | -250.64M | -230.86M | -209.10M |
| Income Before Tax | -257.78M | -243.61M | -293.25M | -273.79M | -253.75M |
| Income Tax Expenses | 283.00K | 178.00K | 446.00K | 393.00K | 268.00K |
| Earnings from Continuing Operations | -258.06 | -243.79 | -293.70 | -274.18 | -254.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -258.06M | -243.79M | -293.70M | -274.18M | -254.02M |
| EBIT | -274.33M | -263.46M | -250.64M | -230.86M | -209.10M |
| EBITDA | -273.70M | -262.83M | -250.00M | -230.20M | -208.43M |
| EPS Basic | -1.61 | -1.53 | -1.88 | -2.56 | -3.47 |
| Normalized Basic EPS | -1.01 | -0.96 | -0.91 | -1.33 | -1.90 |
| EPS Diluted | -1.61 | -1.53 | -1.88 | -2.56 | -3.47 |
| Normalized Diluted EPS | -1.01 | -0.96 | -0.91 | -1.33 | -1.90 |
| Average Basic Shares Outstanding | 641.00M | 637.49M | 629.34M | 516.45M | 387.59M |
| Average Diluted Shares Outstanding | 641.00M | 637.49M | 629.34M | 516.45M | 387.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |